356 / 1631
Which Patients with Stage I-II Hodgkin Lymphoma for
Contemporary Combined Modality Therapy in the PET-CT era ?
• As a treatment option for patients with favorable disease,
especially when
risk of late toxicity of RT considered
lower than risk of relapse (Age, site of disease, sex)
• Older patients – increased risks associated with ABVD
• Definitely for patients with a positive interim PET scan (in
RAPID and EORTC +/- BEACOPP)
• Patients with large mediastinal adenopathy
(younger female
patients always a difficult individual discussion)